Saliva testing for the virus that causes COVID-19 is gaining acceptance in both the scientific community and US market.
Diagnostic Testing and Emerging Technologies
Keeps You Up-to-Date on New Diagnostic Tests, Testing Trends and Opportunities, and Emerging Test Technologies
Subscribe today for access to
Articles and Reports
The FDA recently confirmed that a new rule requiring healthcare providers to notify patients of their breast density status will be released in late 2022 or early 2023.
The new CAP guidance addresses use of immune checkpoint inhibitors for evaluating and treating patients with specific cancers.
What the equity rule is, who it affects, and how to comply.
Despite lessons learned from COVID-19 testing, HHS and FDA plan for monkeypox testing remains flawed.
While new FDA clearances of blood-based early detection tests for Alzheimer’s represent significant progress, limitations remain.
Recent study suggests a new test may help doctors detect Lyme disease during the early stages when treatment is likely to be more effective.
A recent study shows that most patients who underwent such screening were diagnosed at an earlier stage than those who did not.
A recent study shows that combined cardiomyopathy and arrhythmia genetic testing catches things disease-specific testing would miss.
For labs, the big takeaway is how prominently molecular testing and profiling figures in so many aspects of the NCCN’s recommendations.
The agency is advising people to perform repeat, or serial testing after a negative result, regardless of symptoms.
Two recent studies show that most people see telehealth as a supplement to in-person visits, rather than a replacement.